Syquant Capital Sas Spring Works Therapeutics, Inc. Transaction History
Syquant Capital Sas
- $302 Million
- Q2 2025
A detailed history of Syquant Capital Sas transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Syquant Capital Sas holds 247,000 shares of SWTX stock, worth $11.6 Million. This represents 3.85% of its overall portfolio holdings.
Number of Shares
247,000
Previous 247,000
-0.0%
Holding current value
$11.6 Million
Previous $9.85 Million
17.87%
% of portfolio
3.85%
Previous 3.85%
Shares
1 transactions
Others Institutions Holding SWTX
# of Institutions
358Shares Held
63.2MCall Options Held
5.81MPut Options Held
2.55M-
Vanguard Group Inc Valley Forge, PA7.08MShares$333 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$264 Million0.0% of portfolio
-
State Street Corp Boston, MA2.92MShares$137 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.58MShares$121 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA2.14MShares$101 Million0.66% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.93B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...